AWARDED PROJECTS

Development of an Alzheimer’s disease diagnostic based upon an epitope protection assay (2006)

Sector

Human Health

Overview

Ontario-based ProMIS Neurosciences (formerly known as Amorfix Life Sciences Inc.) is using molecular and proteomic techniques to develop a blood test for Alzheimer’s disease. The company has shown that its test can detect aggregated protein (amyloid) in femtogram quantities (ten parts per trillion) when it is spiked into plasma or cerebral spinal fluid. The diagnostic assay is currently being tested in patient samples.